Last reviewed · How we verify
Hexanicit (inositol nicotinate)
Inositol nicotinate (Hexanicit) is a marketed drug primarily indicated for niacin deficiency, positioned as a precursor to niacin, an essential nutrient. Its key strength lies in its unique mechanism of action, providing a different formulation compared to direct nicotinic acid, which has been on the market since 1957. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | inositol nicotinate |
|---|---|
| Drug class | inositol nicotinate |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Niacin deficiency
- Pellagra
Common side effects
Key clinical trials
- Efficacy Study of a Food Supplement With Myo-inositol, N-Acetyl-Cystein, Zinc and Vitamins on Sperm DNA Fragmentation (NA)
- Effects of Dietary Supplements on Response to Air Pollution (NA)
- Effect of Limicol on (LDL)-Cholesterol Levels in Moderate Hypercholesterolaemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hexanicit CI brief — competitive landscape report
- Hexanicit updates RSS · CI watch RSS
- portfolio CI